Metastatic malignant neoplasm

This study tests whether giving a precise, high-dose radiation treatment (SBRT) to bone tumors before surgery is safe and can prevent the cancer from returning. About 39 adults with cancer that has spread to their bones and who need surgery to stabilize a fracture risk will recei…

This study tests two experimental drugs, ERAS-007 and ERAS-601, in people with advanced solid tumors that have not responded to standard treatments. The drugs are taken orally and aim to block signals that help cancer grow. The trial will first find safe doses and then check if t…

This early-phase study tests a new drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to find safe doses and check for side effects. About 90 participants will take pa…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and re…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…

This early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…

This phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tum…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This trial is testing whether giving the cancer drug bortezomib (Velcade) every day, instead of the usual weekly or biweekly schedule, is safe and might work better against advanced or metastatic solid tumors. The study enrolls adults with solid tumors for whom standard treatment…

This early-phase study tested a combination of two drugs, temsirolimus and cetuximab, in 45 adults with advanced or metastatic solid tumors that had not responded to standard treatments. The goal was to check safety and see if blocking two cancer pathways at once could slow tumor…

This study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefi…

This phase 2 trial investigates whether a single, low dose of radiation to the small intestine can help the immune system recognize and attack tumors again in people with advanced solid cancers that have stopped responding to immunotherapy. Participants receive 1Gy of radiation t…

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…

This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…

This study looked at whether adding focused radiation (SBRT) or surgery to standard treatments like chemo or hormone therapy helps people with breast cancer that has spread to just one or two places. 129 participants were randomly assigned to get standard care alone or standard c…

This trial investigates whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a procedure called immunoembolization can help people whose uveal melanoma has spread to the liver. The drugs help the immune system attack cancer cells, while immunoembolization cut…

This phase II trial tests whether radiation therapy can help control cancer that has spread or grown after immunotherapy. About 230 patients with metastatic or lymphoid cancers will receive targeted radiation to see if it stabilizes the disease or shrinks tumors. The study also m…

This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their c…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This early-stage trial tested an experimental drug called LVGN6051, which activates immune cells by targeting CD137, both alone and combined with the approved immunotherapy Keytruda. The study involved 105 adults with advanced or metastatic cancers that had spread. The main goal …

This early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it…

This study tested giving focused radiation before surgery to people with cancer that spread to the brain. The goal was to see if this approach is safe and might lower the chance of the tumor coming back. 26 adults with brain metastases took part. The treatment aims to control the…

This study tested a new drug called MRG004A in 39 adults with advanced or metastatic solid tumors that have a specific marker called tissue factor. The goal was to find the safest dose and see if the drug can shrink tumors. Researchers monitored side effects and how well the drug…

This early-phase trial tested a new drug called M6223, which blocks a protein called TIGIT that can turn off immune cells. M6223 was given alone or together with another drug, bintrafusp alfa, to 58 people with advanced solid tumors that had stopped responding to standard treatme…

This study tested whether a single, high dose of targeted radiation can control cancer that has spread to just a few spots (1-5 tumors). 150 adults with limited metastatic cancer received this treatment to see if it could delay further spread and improve survival. The goal is to …

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…

This early-phase trial tested a combination of three drugs—vemurafenib, cetuximab, and irinotecan—in 47 people with advanced solid tumors that have a specific BRAF V600 mutation and could not be removed by surgery or had spread. The main goal was to find the safest dose and under…

This early-stage trial tested a modified vaccinia virus (VV-GMCSF-Lact) injected directly into tumors of 34 women with recurrent or metastatic breast cancer that no longer responded to standard treatments. The main goal was to check safety and find the highest safe dose. Research…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…

This study tested a new drug called TAK-676, alone and with pembrolizumab, in 248 adults with advanced solid tumors that had no standard treatment options. The main goal was to check safety and find the highest dose that causes few side effects. The study also looked at how well …

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new immune cell therapy called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed by surgery. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The ther…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…

This study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…

This phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabili…

This completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). …

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…

This early-phase study tested a new drug called WTX-330 in 25 adults with advanced solid tumors or lymphoma that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study is now comp…

This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This early-phase study tested a new radioactive drug called [177Lu]Lu-TEFAPI-06 in 5 people with advanced solid tumors that had spread and were no longer responding to standard treatments. The main goal was to check safety and see how the drug moves through the body. Researchers …

This early-phase study tested a new mix of three drugs—IL-15, nivolumab, and ipilimumab—in 31 adults with cancers that no longer respond to standard treatments. The goal was to find the safest dose and see if the combination could help the immune system attack tumors. Participant…

This early-phase study tested a new treatment called NG-350A, a virus designed to target tumors and boost immune activity, combined with the immunotherapy drug pembrolizumab. Fourteen people with advanced epithelial cancers that had stopped responding to standard treatments recei…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…

This study tested a combination of three immunotherapy drugs (ipilimumab, nivolumab, and BMS-986156) with or without precise radiation therapy in 51 people with advanced solid cancers that had spread to the liver or lungs. The goal was to find the safest dose of BMS-986156 and se…

This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but…

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…

This early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. 135 …

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This early-stage study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the safety of the drug and how the body processes it. Thi…

This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…

This phase 2 trial tested whether adding stereotactic body radiation therapy (SBRT) to standard checkpoint immunotherapy improves tumor response in 106 people with advanced metastatic cancer. Participants received either immunotherapy alone or immunotherapy plus SBRT to one tumor…

This study looked at the long-term safety of the drug sacituzumab govitecan (Trodelvy) in 25 people with metastatic solid tumors who were already benefiting from the treatment. Participants continued to receive the drug intravenously, and researchers tracked any side effects or l…

This early-stage trial tested a combination of immune cells in 9 people with stage IV solid tumors that had stopped responding to standard treatments. The main goal was to see if the therapy is safe and to check for any signs that it might control the disease. The study is now co…

This study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and …

This study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or I…

This early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…

This early-stage trial tested a new therapy called SUPLEXA in 46 adults with advanced solid tumors or blood cancers that had spread. SUPLEXA is made from a patient's own immune cells, which are processed in a lab to become more active against cancer. The main goal was to check sa…

This study tested a new radiation technique called SABR in 13 adults with cancer that had spread to more than 10 spots in the body. The goal was to see if giving high-dose, precise radiation to all cancer sites is safe. Researchers looked for side effects and quality of life chan…

This early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…

This study looked at whether using a liquid biopsy (a blood test that detects cancer DNA) early in the diagnostic process could help doctors diagnose and recommend treatment faster for people with advanced lung or gastrointestinal cancer. 463 participants were enrolled across mul…

This study tested a program called PRISM, which teaches skills like stress management and goal setting, to see if it helps racial minority patients with serious illnesses feel more resilient and communicate better with their healthcare providers. The study enrolled 28 seriously i…

This study tested whether an online exercise and education program could help cancer patients and survivors feel better during the COVID-19 pandemic. Thirty adults with metastatic breast or gynecological cancer, or breast cancer survivors, took part. The program aimed to reduce f…

This study looked at whether cancer patients already taking strong opioids like morphine can stop taking paracetamol without their pain getting worse. 204 adults with metastatic cancer and stable pain on both medications were randomly assigned to continue paracetamol or switch to…

This study tested a program called LiveWell, which teaches practical skills to help people with metastatic lung cancer manage stress, anxiety, and sadness. One participant completed the 8-session video-based training. The goal was to see if the program is usable and helpful for i…

This study tested a short talking therapy called CALM for advanced cancer patients with depression. It involved 90 people in Korea and aimed to see if the therapy was practical and helpful. The therapy focuses on managing symptoms, relationships, and finding meaning.

This study tested whether a team of nutrition experts working remotely with doctors could improve the health and well-being of 158 people with stage IV cancer undergoing chemotherapy. The goal was to prevent weight loss, muscle loss, and poor nutrition, which are common but often…

This study tested whether psilocybin, a substance from certain mushrooms, given with therapy could safely reduce anxiety and depression in 55 people with metastatic cancer. Participants received counseling and a pharmaceutical-grade psilocybin dose. The trial focused on safety an…

This phase 1 trial tested whether a second psilocybin-assisted group therapy retreat is safe and helpful for anxiety in 15 patients with metastatic cancer who had only a partial response to their first retreat. Psilocybin, the active ingredient in magic mushrooms, is given in a g…

This study tested a therapy called Managing Cancer and Living Meaningfully (CALM) to see if it helps people with brain cancer feel less distressed. 60 adults with brain tumors or brain metastases who had high depression or death anxiety took part. The study measured how many peop…

This study tested whether supervised breathing exercises could reduce pain, shortness of breath, and improve daily function in 58 terminal-stage cancer patients receiving palliative care. One group did diaphragmatic and pursed-lip breathing with a physiotherapist, while the other…

This study looks at whether analyzing the genes of a tumor (from a tissue sample or a blood test) can help doctors pick a more effective treatment for people with advanced solid cancers that have stopped responding to standard therapies. About 235 participants will have their tum…

This trial is testing whether contrast-enhanced ultrasound (CEUS) can reliably measure tumor blood flow in people with metastatic cancers like GIST, breast, kidney, colon, rectal, or melanoma. Participants will have two ultrasound scans before starting anti-angiogenic treatment, …

This study tests whether analyzing a patient's tumor alongside a sample of their normal tissue can help doctors select a more effective treatment for advanced cancer. The approach aims to provide a personalized therapy choice for every participant, even those without known geneti…

This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand …

This completed study looked at 130 hospitalized cancer patients to see if hand grip strength could predict short-term outcomes like death within 30 days, ICU admission, or hospital readmission. Researchers measured grip strength within 24 hours of admission using a simple, non-in…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This study tested a special communication program for doctors and parents of children with advanced cancer. The goal was to help families and doctors agree on treatment goals, especially for children nearing end of life. Researchers measured whether this improved the child's qual…

This study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…

This study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …

This study aims to develop and validate a scoring system to identify which patients with metastatic breast cancer are likely to live longer with third-line chemotherapy. Researchers will collect clinical, histological, and biological data from 267 women starting a third line of t…

This study tested whether a planned meeting between a hospitalized cancer patient, their family doctor, and a specialist could reduce unplanned hospital visits. 667 adults with metastatic solid tumors were randomly assigned to either the standard discharge process or this organiz…

This study tested a program called ED GOAL that helps older adults with serious illnesses like heart failure or cancer discuss their end-of-life wishes with doctors and family, starting in the emergency department. Researchers enrolled 141 patients and measured whether the progra…

This study tested a website designed to help people with advanced cancer plan for end-of-life care, including medical wishes, legal documents, and financial tasks. About 100 patients took part to see if the tool reduced distress and improved planning. The goal was to learn whethe…

This study tested whether a blood test can find tumor cells or substances released by intestinal polyps. Researchers compared blood samples from 120 people with and without polyps during a colonoscopy. The goal is to see if these markers could help predict or monitor cancer sprea…

This study looked at whether a special planning tool, called a POST form, helps older adults (65+) get the medical care they prefer at the end of life. Researchers worked with 389 people, including those with dementia, to see if their treatment matched their wishes. The goal was …

This study tested whether choosing cancer drugs based on the genetic makeup of a patient's tumor works better than standard treatment. It included 742 adults with advanced solid tumors that had stopped responding to usual therapies. Patients were randomly assigned to receive eith…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This completed study aimed to create a biobank of 'organoids'—tiny, 3D mini-tumors grown from liver cancer tissue. Researchers collected samples from 48 patients with colorectal cancer that spread to the liver or with primary liver cancer. The goal was to see if they could reliab…

This study tested whether giving cancer patients and their families a booklet of questions before a palliative care consultation helps them ask more questions or express more concerns. 121 adults with metastatic cancer and limited life expectancy took part. The booklet covered ei…

This completed study examined tumor samples from 3820 people with advanced solid tumors to find how many have NTRK gene fusions. Researchers used genetic testing to identify these rare changes. The study did not test any treatment, but aims to guide future targeted therapy decisi…

This completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these …

This completed study reviewed medical records of 1,250 advanced cancer patients who visited the emergency department. Researchers looked at factors like age, tumor type, and blood test results to see which patients were at higher risk of dying within 90 days. The goal is to help …

This study tested a program called PLAN to help Latino cancer patients plan for their future medical care. Twenty-seven patients with advanced cancer took part. The program aimed to improve their understanding and communication about advance care planning with doctors and family.…